UnitedHealth Group Incorporated (NYSE:UNH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Thursday.
According to Zacks, “Shares of UnitedHealth Group outperformed the industry in past six months. Robust Government business and continued strong performance at Optum are driving the company’s long-term growth. International business and strong capital position are its other positives. It has been witnessing an increase in membership for the past many years. On the back of its impressive earnings in the first nine months, the company raised its 2017 guidance. It has reduced exposure to the troubled public exchange business. Though this move will shield it from losses in this business, premium revenues are likely to be affected. Charges related to Penn Treaty are other causes of concern.”
Several other equities analysts have also issued reports on the stock. Mizuho reaffirmed a “buy” rating on shares of UnitedHealth Group in a report on Tuesday, October 24th. Argus boosted their price objective on shares of UnitedHealth Group from $215.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, October 19th. Sanford C. Bernstein reissued an “outperform” rating and set a $219.00 price objective (up from $210.00) on shares of UnitedHealth Group in a report on Thursday, October 19th. Oppenheimer Holdings, Inc. boosted their price objective on shares of UnitedHealth Group from $215.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Finally, Bank of America Corporation boosted their price objective on shares of UnitedHealth Group from $230.00 to $240.00 and gave the company a “buy” rating in a report on Wednesday, October 18th. Three investment analysts have rated the stock with a hold rating and twenty-four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $215.27.
UnitedHealth Group (NYSE:UNH) last released its quarterly earnings results on Tuesday, October 17th. The healthcare conglomerate reported $2.66 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.57 by $0.09. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The business had revenue of $50.32 billion for the quarter, compared to analyst estimates of $50.38 billion. During the same period in the previous year, the company earned $2.17 earnings per share. The business’s revenue for the quarter was up 8.7% on a year-over-year basis.
ILLEGAL ACTIVITY NOTICE: “UnitedHealth Group Incorporated (UNH) Downgraded by Zacks Investment Research” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/02/unitedhealth-group-incorporated-unh-downgraded-by-zacks-investment-research.html.
In other UnitedHealth Group news, Director Richard T. Burke sold 15,000 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $191.71, for a total transaction of $2,875,650.00. Following the sale, the director now directly owns 1,818,898 shares in the company, valued at approximately $348,700,935.58. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gail R. Wilensky sold 5,600 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $199.49, for a total transaction of $1,117,144.00. Following the sale, the director now owns 60,834 shares in the company, valued at $12,135,774.66. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,149 shares of company stock worth $14,212,342. Company insiders own 0.89% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. Dorsey Wright & Associates raised its holdings in shares of UnitedHealth Group by 11.1% in the 1st quarter. Dorsey Wright & Associates now owns 11,522 shares of the healthcare conglomerate’s stock valued at $1,890,000 after purchasing an additional 1,147 shares in the last quarter. Strategic Advisors LLC raised its holdings in shares of UnitedHealth Group by 19.5% in the 1st quarter. Strategic Advisors LLC now owns 2,339 shares of the healthcare conglomerate’s stock valued at $384,000 after purchasing an additional 382 shares in the last quarter. Point View Wealth Management Inc. raised its holdings in shares of UnitedHealth Group by 7.2% in the 1st quarter. Point View Wealth Management Inc. now owns 7,061 shares of the healthcare conglomerate’s stock valued at $1,158,000 after purchasing an additional 476 shares in the last quarter. Harbour Investment Management LLC acquired a new stake in shares of UnitedHealth Group in the 1st quarter valued at $1,374,000. Finally, Suntrust Banks Inc. raised its holdings in shares of UnitedHealth Group by 8.5% in the 1st quarter. Suntrust Banks Inc. now owns 260,811 shares of the healthcare conglomerate’s stock valued at $42,774,000 after purchasing an additional 20,541 shares in the last quarter. Institutional investors own 86.14% of the company’s stock.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.